Trifork Group Sells Partial Stake in Labs Portfolio to Verdane for €22.8M
Event summary
- Trifork Group AG has agreed to sell a portion of its Trifork Labs portfolio to Verdane for €22.8 million in cash, with additional earnout payments tied to future performance.
- The deal includes stakes in Axoniq B.V., Dawn Holding ApS, Frameo ApS, and the full sale of XCI Holding A/S, representing 55% of Trifork Labs' total book value as of March 31, 2026.
- Trifork proposes an extraordinary dividend of DKK 3.00 per share, subject to transaction completion, with proceeds also earmarked for bolt-on acquisitions and organic growth initiatives.
- Verdane, a €10 billion European investment firm, will co-own the assets with Trifork, bringing strategic support and follow-on investment capacity.
The big picture
Trifork Group’s divestment reflects a broader trend among tech investors to monetize minority stakes while retaining upside, leveraging specialized growth-stage partners like Verdane. The move aligns with Trifork’s strategy to focus on core business expansion and shareholder returns, amid a competitive landscape for scaling software-enabled businesses in Europe.
What we're watching
- Execution Risk
- Whether Trifork can successfully deploy the remaining proceeds to accelerate its core business growth through bolt-on acquisitions.
- Portfolio Performance
- The pace at which Verdane and Trifork realize value from the retained stakes in Axoniq, Dawn Health, and Frameo.
- Strategic Alignment
- How the partnership with Verdane will influence future exits or distributions from Trifork’s LabsX portfolio.
Related topics